Aceso Life Science Group Limited (HKG:0474)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Property Leasing	-68.00M	25.00M	29.00M	31.00M	45.00M
Rental and Sale of Construction Machinery and Spare Parts	-	133.00M	153.00M	227.00M	165.00M
Provision of Repair and Maintenance and Transportation Service	-	6.00M	6.00M	8.00M	10.00M
Money Lending	-	-56.00M	-85.00M	30.00M	46.00M
Provision of Asset Management, Securities Brokerage and Other Financial Services	-	10.00M	7.00M	14.00M	14.00M
Unallocated Finance Costs	-	-96.00M	-111.00M	-101.00M	-126.00M
Unallocated Reversal of Impairment Losses of Financial Assets (Expected Credit Losses)	-	-94.00M	14.00M	9.00M	11.00M
Total	-68.00M	-72.00M	13.00M	218.00M	165.00M

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Hong Kong	145.00M	174.00M	256.00M	243.00M
United Kingdom	50.00M	54.00M	55.00M	71.00M
Macau	-	-	1.00M	1.00M
Total	195.00M	228.00M	312.00M	315.00M

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 19, 2026

Data Sources Report a data error